programmed cell death protein 1 inhibitor + sargramostim + thymalfasin

The combination of a programmed cell death protein 1 (PD-1) inhibitor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and thymosin alpha-1 (thymalfasin) is an experimental chemo-free immunotherapy regimen, often referred to as the **GTP regimen**. Developed and primarily investigated by researchers at **Jiangsu Cancer Hospital**, this triple combination is designed to overcome resistance to standard checkpoint inhibitor monotherapy in patients with advanced **solid tumors**. The mechanism of action involves a multi-pronged approach to immune activation: the PD-1 inhibitor (such as sintilimab or camrelizumab) releases the "brakes" on T-cells; GM-CSF (sargramostim) acts as a potent cytokine to stimulate the production and maturation of dendritic cells, enhancing antigen presentation; and thymosin alpha-1 (thymalfasin) serves as an immunomodulator that promotes T-cell differentiation and reduces T-cell apoptosis. By combining these agents, the regimen aims to transform "cold" tumors into "hot" tumors by improving the recruitment and activation of immune cells within the tumor microenvironment. Clinical trials, including Phase 2 studies, have evaluated this regimen in patients who have progressed on prior lines of therapy, showing promising efficacy and a manageable safety profile.

Other names

GTPPD-1 inhibitor + GM-CSF + Tα1PD-1 inhibitor + GM-CSF + Thymosin alpha-1